Who Paid My Doc
Scott Peak
Neurological Surgery Redwood City, CA Medical Doctor
NPI 1326066671 CMS profile 771231
1150 Veterans Blvd, Kaiser Permanente Department Of Neurosurgery 3Rd Floor, Redwood City, CA 94063
General payments
$136
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$88,401
Through program year 2024, Scott Peak of Redwood City, CA is reported in the CMS Open Payments database as having received $136 across 2 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $88,401 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 10th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $15 | 1 | |
| 2022 | General | $121 | 1 |
Beside peers
- Scott Peak
- Neurological Surgery median
- Middle half of Neurological Surgery
- National median
In program year 2025, general payments to Scott Peak were reported at $0. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.
Show as a table
| Year | Scott Peak | Neurological Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $582 | $138–$3,006 | $163 |
| 2020 | $0 | $294 | $76–$2,174 | $114 |
| 2021 | $0 | $387 | $105–$2,432 | $132 |
| 2022 | $121 | $542 | $139–$2,989 | $149 |
| 2023 | $0 | $534 | $145–$2,697 | $160 |
| 2024 | $15 | $574 | $155–$3,046 | $164 |
| 2025 | $0 | $596 | $159–$3,102 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
345
Drug cost
$1,693,497
Branded share of claims
21.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Voranigo Vorasidenib Citrate | Brand | 19 | $837,055 | |
| Tibsovo Ivosidenib | Brand | 27 | $826,056 | |
| Gleostine Lomustine | Brand | 16 | $19,788 | |
| Levetiracetam | Generic | 89 | $4,178 | |
| Lacosamide | Generic | 17 | $2,076 | |
| Dexamethasone | Generic | 25 | $1,504 | |
| Lamotrigine | Generic | 35 | $1,095 | |
| Methylphenidate Hcl | Generic | 18 | $579 | |
| Memantine Hcl | Generic | 28 | $459 | |
| Ondansetron Hcl | Generic | 36 | $321 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| JELMYTO |
|
$15 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurological Surgery in California
Christopher Ames
Neurological Surgery · San Francisco, CA
Larry Khoo
Neurological Surgery · Los Angeles, CA
Samy Abdou
Neurological Surgery · San Diego, CA
Bret Abshire
Neurological Surgery · Murrieta, CA
William Taylor
Neurological Surgery · San Diego, CA
Tooraj Gravori
Neurological Surgery · Encino, CA
Related records
Neurological Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Neurological Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.